SCAMS-R-US

[XenaLives]

SLS - look at this case history

CVI was the axe here, GALE did R/S in 1/18. I've never seen a chart quite like the one posted at the bottom.

GALE,NOW=TRADING-AS-SLS/POST-SPLIT:CEO COMPENSATION=OF INTEREST to shareholders who got scre#ed as always in the dilution of their value:

the entire prev. Board & Management of Galena resigned upon this change, but they wanted to make sure new CEO is taken care of:
Only hope is he affects sale/merger but so far these changes have been detrimental to shareholder value, just keeping the lights on somehow:

someone will write Galena's story as legalized mafia-style theft from the public under the SEC's nose: is this the worst-performing stock ever? Not long ago it was ranked among the 5 worst, anyway:

https://globenewswire.com/news-release/2017/12/29/1276660/0/en/Galena-Biopharma-Inc-Stockholders-Approve-Business-Combination-with-SELLAS-Life-Sciences-Group-Ltd-Board-Sets-Reverse-Stock-Split-Ratio.html


Angelos M. Stergiou, M.D., Sc.D. h.c.

In September 2016, Private SELLAS entered into an employment agreement with Dr. Stergiou, the Registrant's newly appointed chief executive officer, which continues to govern Dr. Stergiou's employment with the Registrant following the Merger. Under this employment agreement, Dr. Stergiou is entitled to an annual base salary of $400,000 (subject to review and adjustment in the discretion of the board of directors or its compensation committee) and a discretionary annual cash bonus, with a target amount no less than 30% of Dr. Stergiou's then
effective base salary (subject to continued employment and the achievement of certain performance objectives established by the employer's board of directors or compensation committee). This employment agreement also provides that Dr. Stergiou will receive a monthly housing allowance of $10,000 and may be eligible to receive an additional discretionary bonus as determined by the employer in its sole discretion.

Dr. Stergiou's employment agreement also provides for additional bonuses in the event of an initial public offering ("IPO") or trade sale by Private SELLAS, in each case that meets certain terms. The Merger is not considered an IPO or trade sale for purposes of Dr. Stergiou's employment agreement, and Dr. Stergiou is not eligible to receive the IPO bonuses or a trade sale bonus in connection with the Merger.

In connection with Dr. Stergiou entering into his employment agreement, and pursuant to the terms thereof, Private SELLAS issued to Dr. Stergiou 827 Private SELLAS restricted stock units ("RSUs") on November 22, 2016. Dr. Stergiou's Private SELLAS RSUs were scheduled to vest on November 22, 2017 and were subject to accelerated vesting upon a change in control of Private SELLAS and certain terminations of employment; however, on August 7, 2017, the board of directors accelerated the vesting of such Private SELLAS RSUs in full and Private SELLAS shares were issued to Dr. Stergiou upon settlement of the Private SELLAS RSUs.

Dr. Stergiou's employment agreement does not have a specified term and either party may terminate Dr. Stergiou's employment agreement by providing written notice at any time, with or without cause. If the employer terminates Dr. Stergiou's employment without cause or Dr. Stergiou resigns for good reason, Dr. Stergiou will be eligible to receive a lump-sum payment equal to two years of his annual base salary. In addition, if such termination or resignation occurs within one month prior to or twelve months following a change in control, Dr. Stergiou will be eligible to receive full vesting of his then outstanding stock awards and any options held by Dr. Stergiou may be exercised during the 12 month period following termination, or if earlier, the expiration date of the options. The employer must provide Dr. Stergiou with six months' notice prior to a termination without cause and may elect to place Dr. Stergiou on garden leave (with base salary and other benefits) during such period. Upon termination of his employment due to death or disability, Dr. Stergiou is eligible for a pro-rated bonus for the year in which terminated.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137607033

After re-listing


Current: